hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06323642 id: F.1-1/20ERB/SZABMU/941 briefTitle: Role of Probiotics as Adjunct Therapy Along With Standard Care in Decreasing Hospital Stay and Improving Symptoms in Pediatric Patients Admitted With Severe Pneumonia overallStatus: RECRUITING date: 2023-09-01 date: 2024-03-31 date: 2024-03-31 date: 2024-03-21 date: 2024-03-21 name: Shaheed Zulfiqar Ali Bhutto Medical University class: OTHER briefSummary: Probiotics as adjuvant therapy along with standard care can decrease hospital stay and improve symptoms (fever, tachypnea,cough) in pediatric patients admitted with severe pneumonia. conditions: Pneumonia conditions: Probiotics studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: randomized control trial primaryPurpose: TREATMENT masking: SINGLE maskingDescription: The patients and their parents/attendants will be kept blind to the fact that they are receiving either probiotic or placebo whoMasked: PARTICIPANT count: 60 type: ESTIMATED name: probiotic containing Lactobacillus rhamnosus GG. name: placebo measure: Number of days in hospital measure: Number of days with cough, fever sex: ALL minimumAge: 6 Months maximumAge: 2 Years stdAges: CHILD facility: Pakistan Institute of Medical Sciences status: RECRUITING city: Islamabad state: Punjab zip: 12000 country: Pakistan name: Nighat Haider, FCPS role: CONTACT phone: 03212125768 email: nighathaider@hotmail.com name: rashiqa saadat, MBBS role: PRINCIPAL_INVESTIGATOR lat: 33.72148 lon: 73.04329 hasResults: False
nctId: NCT06323629 id: STUDY006201 briefTitle: Effects of Recursive Self-feedback on Speech Production in Aphasia overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2025-03 date: 2025-03 date: 2024-03-21 date: 2024-03-21 name: University of South Florida class: OTHER name: Center for Smart Use of Technologies to Assess Real-world Outcomes briefSummary: The goal of this clinical trial is to test the effects of recursive self-feedback procedures on spontaneous speech production in stroke survivors with impaired speech production (aphasia). The main question it aims to answer is:
* Researchers will compare the experimental treatments to see if both have similar effects on improving spontaneous speech production. conditions: Aphasia conditions: Stroke studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: SINGLE whoMasked: OUTCOMES_ASSESSOR count: 45 type: ESTIMATED name: Adaptive recursive self-feedback procedure name: Non-adaptive recursive self-feedback procedure measure: Speaking rate measure: Speech initiation latency in milliseconds sex: ALL minimumAge: 18 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06323616 id: 2023/2343 briefTitle: The Effect of Anesthesia Depth Monitoring on Emergence Delirium in Pediatrics overallStatus: RECRUITING date: 2024-03-25 date: 2024-08-01 date: 2024-09-01 date: 2024-03-21 date: 2024-03-21 name: Istanbul University class: OTHER briefSummary: Some changes in the patient's cognitive state are observed during the recovery period from general anesthesia. This period of behavioral dysregulation has been called emergence agitation (EA) and emergence delirium (ED). ED and EA occur in the early postoperative period (often within the first 30 minutes). The incidence of ED ranges from 10% to 80% in children and is described as a distressing clinical condition by 42% of pediatric anesthesiologists. Self-harm by the child increases the risk of delayed discharge and may increase the cost of medical care.
In the literature, the Pediatric Anesthesia Rescue Delirium (PAED) Scale Score is used in the diagnosis of ED and EA. This score consists of 5 criteria (maximum score 20) scored using 0-4 point scales. These criteria; The child needs to make eye contact with the caregiver, the child's movements are purposeful, the child is aware of the environment, the child is restless/angry, the child cannot be consoled. While the sensitivity of ≥10 points for the diagnosis of ED is 64% and the specificity is 86%, the sensitivity of \>12 points for the diagnosis of ED is 100% and the specificity is 94.5%.
Monitoring intraoperative depth of anesthesia in the adult population has been recommended by the American Society of Anesthesiologists (ASA) due to its potential benefits such as faster recovery time and lower drug dosage, as well as prevention of adverse effects such as the incidence of hypotension. The use of anesthesia depth monitors used so far for children is controversial because brain development in children has not yet been completed and the calculation algorithms of these indices are based on adult EEG characteristics.
There are very few studies in the literature on the relationship between anesthesia depth monitoring and EA/ED in children, and further studies are needed. conditions: Anesthesia conditions: Emergence Delirium conditions: Anesthesia Awareness conditions: Behavior Child Problems conditions: Postoperative Delirium conditions: Postoperative Complications studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Randomized, Single-Blind, Prospective, Interventional primaryPurpose: SCREENING masking: DOUBLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER count: 270 type: ESTIMATED name: MAC adjustment to PSI between 25 and 50 measure: ED/EA incidence measure: mYPAS measure: PSI <25 episode duration measure: PSI >50 episode duration measure: PSI <25 number of episodes measure: PSI >50 number of episodes measure: Suppresyon ratio measure: SEF95R measure: SEF95L measure: Mean blood pressure measure: Heart rate measure: SpO2 measure: Total amount of sevoflurane used measure: Total amount of remifentanil used measure: MAC measure: Waking up time measure: Pupil size measure: Anesthesia duration measure: Surgery duration measure: PHBQ measure: Ped-PADS measure: Time of discharge from hospital sex: ALL minimumAge: 2 Years maximumAge: 8 Years stdAges: CHILD facility: Istanbul University status: RECRUITING city: Istanbul country: Turkey name: Meltem Savran Karadeniz, Assoc. Prof. role: CONTACT phone: 009005334845563 email: mskaradeniz@gmail.com lat: 41.01384 lon: 28.94966 facility: Istanbul University status: RECRUITING city: Istanbul country: Turkey lat: 41.01384 lon: 28.94966 hasResults: False
nctId: NCT06323603 id: 3-1 briefTitle: Biomonitoring of Occupationally Populations Exposed to Micro and Nanoplastic overallStatus: RECRUITING date: 2023-06-30 date: 2024-06 date: 2024-09 date: 2024-03-21 date: 2024-03-25 name: Ricard Marcos class: OTHER name: Finnish Institute of Occupational Health briefSummary: The biomonitoring study aims to evaluate genotoxic damage and other parameters of exposure in different occupational exposed populations that work directly with different plastics. conditions: Occupational Exposure conditions: Genotoxicity conditions: Damage Dna studyType: OBSERVATIONAL observationalModel: CASE_CONTROL timePerspective: CROSS_SECTIONAL count: 45 type: ESTIMATED name: Micro and nanoplastic measure: Characterization of macro and nanoplastics measure: Genotoxic evaluation by the Micronucleus assay measure: Genotoxic evaluation by the Comet assay measure: Cytokine release measure: Microbiota analysis from feces by MinIOn measure: Analyses of surrogate biomarkers sex: ALL minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Textile industry status: COMPLETED city: Helsinki country: Finland lat: 60.16952 lon: 24.93545 facility: Recycling company status: COMPLETED city: Alicante country: Spain lat: 38.34517 lon: -0.48149 facility: Textile Industry status: COMPLETED city: Alicante country: Spain lat: 38.34517 lon: -0.48149 facility: Control recruitment status: RECRUITING city: Barcelona country: Spain name: Susana Pastor role: CONTACT lat: 41.38879 lon: 2.15899 hasResults: False
nctId: NCT06323590 id: UAB 2372 id: UAB type: OTHER domain: UAB briefTitle: Refining the Role of Mid-induction Bone Marrow Biopsy in Acute Myeloid Leukemia: A Pilot Study overallStatus: NOT_YET_RECRUITING date: 2024-05 date: 2028-05 date: 2028-05 date: 2024-03-21 date: 2024-03-21 name: University of Alabama at Birmingham class: OTHER briefSummary: The purpose of the study is to observe the outcomes of patients with acute myeloid leukemia who do not receive an immediate second round of chemotherapy after undergoing a standard mid-induction bone marrow biopsy. conditions: Acute Myeloid Leukemia studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 60 type: ESTIMATED measure: rates of complete remission sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: University of Alabama at Birmingham city: Birmingham state: Alabama zip: 35294 country: United States name: Omer Jamy role: CONTACT phone: 205-934-2721 email: omerjamy@uabmc.edu name: Omer Jamy role: CONTACT phone: 2059342721 email: omerjamy@uabmc.edu name: Omer Jamy role: PRINCIPAL_INVESTIGATOR lat: 33.52066 lon: -86.80249 hasResults: False
nctId: NCT06323577 id: TUH rKA vs MA TKA briefTitle: Comparing Efficacy Between Restricted Kinematic Alignment vs Mechanical Alignment in Bilateral TKA overallStatus: RECRUITING date: 2024-03-14 date: 2026-05-31 date: 2026-05-31 date: 2024-03-21 date: 2024-03-21 name: Thammasat University Hospital class: OTHER briefSummary: The goal of this RCT is to investigate efficacy between restricted kinematic alignment and mechanical alignment TKA in simultaneous bilateral TKA patients.
* Does rKA have lower pain score than MA in simultaneous bilateral TKA patients? Participants will undergo simultaneous bilateral TKA and randomized one side will use rKA and the other side will use MA. conditions: Osteoarthritis, Knee conditions: TKA studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: TRIPLE whoMasked: PARTICIPANT whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 50 type: ESTIMATED name: Restricted kinematic alignment name: Mechanical alignment measure: Forgotten joint score measure: Modified WOMAC score measure: Range of motion measure: Pain score measure: Hip knee ankle angle measure: Complications measure: Incidence of soft tissue releasing sex: ALL minimumAge: 40 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Thammasat University status: RECRUITING city: Khlong Luang state: Pathum Thani zip: 12120 country: Thailand name: Yot Tanariyakul, M.D. role: CONTACT phone: 663930257 email: y.tanariyakul@gmail.com name: Nattapol Tammachote, M.D. role: PRINCIPAL_INVESTIGATOR lat: 14.06467 lon: 100.64578 hasResults: False
nctId: NCT06323564 id: 21C223 briefTitle: Exploring Emotional Intelligence and Cognitive Flexibility in Anorexia Nervosa and Parkinson's Disease. acronym: INTELLEGO overallStatus: RECRUITING date: 2023-01-13 date: 2024-08-13 date: 2025-01-13 date: 2024-03-21 date: 2024-03-21 name: Istituto Auxologico Italiano class: OTHER briefSummary: The main aim of this study is to demonstrate how disorders characterized by different types of "inflexibility", cognitive-affective type for Anorexia nervosa and motor one for Parkinson's disease, have an impact on how emotional stimuli are processed and on the transition within emotional states. conditions: Anorexia Nervosa conditions: Parkinson Disease studyType: OBSERVATIONAL observationalModel: CASE_CONTROL timePerspective: PROSPECTIVE count: 80 type: ESTIMATED name: Neuropsychological tests in PD name: Self-report questionnaires in PD name: International Affective Picture System (IAPS) name: Neuropsychological tests in AN name: Self-report questionnaires in AN name: Analysis of bio-humoral parameters measure: Change in International Affective Picture System (IAPS) measure: Change in self-report questionnaires - STAI measure: Change in self-report questionnaires - BDI measure: Change in Heart rate variability measure: Change in analysis of bio-humoral parameters sex: ALL minimumAge: 18 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Istituto Auxologico Italiano status: RECRUITING city: Oggebbio zip: 28824 country: Italy name: Riccardo Cremascoli, MD, PhD role: CONTACT lat: 45.99088 lon: 8.64663 hasResults: False
nctId: NCT06323551 id: 2023/50 briefTitle: The Effect of Mother's Smell and Breast Milk Smell on Pain overallStatus: RECRUITING date: 2024-03-14 date: 2024-07-14 date: 2024-12-24 date: 2024-03-21 date: 2024-03-25 name: Tarsus University class: OTHER briefSummary: The research was planned as a randomized controlled study to investigate the effect of breast milk smell and mother's smell applied while heel blood was taken to term babies in the Mersin City EAH Neonatal Intensive Care Unit between October and December 2023, on acute pain and crying duration. During the heel prick procedure, which is routinely performed in the neonatal intensive care unit, no pharmacological/non-pharmacological method will be applied to the control group to reduce the baby's pain before, during and after the heel prick. The baby's pain score will be evaluated by the observing nurse according to the NIPS pain scale 5 minutes before, during and 5 minutes after the procedure.
In the study group that will be made to smell the mother's scent; The mother of each baby whose heel blood will be taken will be given a specially made cover made of 100% cotton yarn, sterilized the day before, and the mother will be asked to put the cover on her bare skin (on her bare skin) after the shower and to keep the cover on the mother's chest for one night (8 hours). It will be placed 15 cm away from the baby and smelled 5 minutes before and 5 minutes after the heel prick attempt. The baby's pain score will be evaluated by the observing nurse according to the NIPS pain scale 5 minutes before, during and 5 minutes after the procedure. conditions: Newborn; Vitality conditions: Pain conditions: Crying studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: randomized controlled primaryPurpose: OTHER masking: NONE count: 90 type: ESTIMATED name: Mother's Smell name: Mother's Breast Milk Smell measure: Neonatal Infant Pain Scale measure: criying time sex: ALL minimumAge: 1 Day maximumAge: 15 Days stdAges: CHILD facility: Tarsus State Hospital status: RECRUITING city: Mersin country: Turkey name: Atiye Karakul, Ass. Prof. role: CONTACT phone: 90(324) 600 00 33 phoneExt: 2231 email: atiyekarakul@gmail.com lat: 36.79526 lon: 34.61792 hasResults: False
nctId: NCT06323525 id: CHN-PLAGH-BT-083 briefTitle: TCR Reserved and Power3 Gene Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B Cell Lymphoma overallStatus: RECRUITING date: 2024-04-17 date: 2026-04-25 date: 2027-04-25 date: 2024-03-21 date: 2024-04-18 name: Chinese PLA General Hospital class: OTHER briefSummary: The safety and efficacy of the chimeric antigen receptor (CAR)-T, a CD19-targeting, TRAC and Power3 double genes deleted allogeneic CAR-T cell product, are undergoing rigorous evaluation in non-Hodgkin's lymphoma (NHL) subjects from our ATHENA trial (NCT06014073). Unexpectedly, expansion of the initial residual CD3-positive CAR T from products were measured in patients' peripheral blood (PB) without exception. Accompanying with host immune reconstitution and appearance of the detectable B cells, the CD3-positive allogenic CAR T cells exhibited a compelling amplification advantage over CD3-negative CAR T cells. The amplification of CD3-positive CAR T cell population dynamically suppressed host B cell recovery, and presumably surveilled the recurrence or progression of tumors, but did not induce typical Graft-versus-host-disease (GvHD). Additionally, a series of in vitro experiments illustrated that the HLA-mismatched fratricide between host T cells and TCR-reserved Power3-deleted allogenic CAR T cells was markedly slashed, which in combination with our observed clinical safety date supported the notion that only genomic deletion of Power3 gene in allo-CAR T cells is sufficient to overcome GvHD and host T cell-mediated rejection response.
In the ATHENA-2 study, our design is to preserve the expression of the TCR on T cells from healthy donors while selectively disabling the Power3 gene to prepare ATHENA-2 CAR T cells. This approach harnesses the tonic signaling of CAR T cells, resulting in enhanced persistence and improved response to treatment. The purpose of this study is to evaluate the safety and efficacy of ATHENA-2 in B-cell NHL. conditions: Non-hodgkin Lymphoma studyType: INTERVENTIONAL phases: PHASE1 phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 30 type: ESTIMATED name: TCR reserved and Power3 gene knock-out allogeneic CD19-targeting CAR-T cell (ATHENA-2 CAR-T) name: Fludarabine name: Cyclophosphamide measure: Phase 1: Incidence of adverse events (AEs) defined as DLT measure: Phase 1: Recommended phase 2 dose (RP2D) measure: Phase 2: 3-month objective response rate (ORR) measure: Phase 2: Complete response (CR) rate measure: Phase 2: Duration of Response (DOR) measure: Phase 2: Overall Survival (OS) measure: Phase 2: Progression Free Survival (PFS) measure: Phase 1 and phase 2: Pharmacokinetics: Level of ATHENA-2 CAR-positive T cells circulating in blood over time measure: Phase 1 and phase 2: Pharmacodynamics: Level of CD19+ cells in peripheral blood measure: Phase 1 and phase 2: Level of serum cytokines in peripheral blood measure: Phase 1: 3-month ORR measure: Phase 1: OS measure: Phase 1: PFS measure: Phase 2: Incidence of AEs measure: Phase 1: Level of donor-specific antibody (DSA) in blood. measure: Phase 1: Level of human anti-mouse antibodies (HAMA) sex: ALL minimumAge: 18 Years maximumAge: 70 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Biotherapeutic Department of Chinese PLA General Hospital status: RECRUITING city: Beijing state: Beijing zip: 100853 country: China name: Weidong Han, M.D role: CONTACT phone: +86-010-66937463 email: hanwdrsw@sina.com name: Qingming Yang, M.D role: SUB_INVESTIGATOR name: Yang Liu, M.D role: SUB_INVESTIGATOR name: Jinhong Shi, M.S role: SUB_INVESTIGATOR name: Chunmeng Wang, M.S role: SUB_INVESTIGATOR lat: 39.9075 lon: 116.39723 facility: Biotherapeutic Department of Chinese PLA General Hospital status: RECRUITING city: Beijing country: China name: Weidong Han, Ph.D role: CONTACT phone: +86-010-55499341 email: hanwdrsw@sina.com lat: 39.9075 lon: 116.39723 facility: EdiGene Inc status: RECRUITING city: Beijing country: China name: Zixuan Pang, Ph.D role: CONTACT phone: 010-80733899 email: zxpang@edigene.com lat: 39.9075 lon: 116.39723 facility: School of Life Sciences, Peking University status: RECRUITING city: Beijing country: China name: Wensheng Wei, Ph.D role: CONTACT phone: 010-62757794 email: wswei@pku.edu.cn lat: 39.9075 lon: 116.39723 hasResults: False
nctId: NCT06323512 id: Nanjing briefTitle: Pulmonary Arteyr Denervation for Heart Failure overallStatus: NOT_YET_RECRUITING date: 2024-06-01 date: 2024-11-01 date: 2025-12-30 date: 2024-03-21 date: 2024-04-24 name: Nanjing First Hospital, Nanjing Medical University class: OTHER briefSummary: Prolonged pulmonary venous congestion culminates in pulmonary hypertension, defined as a mean pulmonary arterial pressure \> 20 mmHg and pulmonary artery wedge pressure \>15 mmHg at rest, as determined by right heart catheterization. Pulmonary hypertension secondary to heart failure (PH-HF) is further stratified into isolated post-capillary pulmonary hypertension (Ipc-PH, pulmonary vascular resistance (PVR) is ≤2 Woods Unit) and combined pre- and post-capillary pulmonary hypertension (Cpc-PH, PVR \> 2 Woods Unit), the later reflecting additional pulmonary vascular constriction or remodeling in addition to passive PH. While medications tailored for World Health Organization defined Group I pulmonary arterial hypertension are not endorsed for PH-HF according to current guidelines, the coexistence of pulmonary hypertension exacerbates the severity of heart failure. Given the presence of pulmonary arterial vasoconstrictor and heightened sympathetic nervous activity in patients with heart failure, the PADN-5 study has demonstrated the safety and efficacy of pulmonary artery denervation (PADN) for patients with CpcPH, characterized by the improvements in left ventricular ejection fraction, cardiac output, clinical outcome, and reductions in left atrial pressure, pulmonary arterial pressure, and PVR. Our objective is to assess the feasibility, safety, and efficacy of PADN for patients with heart failure independent of left ventricular ejection fraction (HFrEF or HFpEF) without pulmonary hypertension (N=30, 15 with HFrEF and another 15 with HFpEF). conditions: Heart Failure studyType: OBSERVATIONAL observationalModel: CASE_ONLY timePerspective: PROSPECTIVE count: 20 type: ESTIMATED name: Pulmonary artery denervation (PADN) measure: Left ventricular ejection fraction measure: Tricuspid annuls peak systolic excursion (TAPSE) measure: 6 minute walk distance changes measure: All-cause death measure: Rehospitalization measure: NT-proBNP measure: Superoxide dismutase (SOD) 3 measure: Plasma noradrenaline measure: All outcomes will be stratified by HFrEF and HFpEF sex: ALL minimumAge: 18 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06323499 id: UK Essen briefTitle: Outcome of Induced Atypical Atrial Flutter overallStatus: COMPLETED date: 2018-04-01 date: 2021-10-31 date: 2021-10-31 date: 2024-03-21 date: 2024-04-24 name: University Hospital, Essen class: OTHER briefSummary: Background: Atypical atrial flutter (AAF) is an increasingly relevant clinical problem. Despite advancements in mapping and ablation techniques, the general management of these patients remain challenging especially when mapping cannot be performed during ongoing arrhythmia. There are no data whether induction of AAF is a feasible approach in these cases.
For this retrospective study, the investigators analyzed patients undergoing ablation of AAF between April 2018 and January 2021 that were identified from the ablation database at the West German Heart and Vascular Center, Essen. All patients were followed up in the outpatient clinic as part of the clinical standard routine or contacted by telephone to assess the occurrence of clinical recurrence of any arrhythmia. In case the documentation was not performed at the institution, relevant documents and ECGs were requested and reviewed.
The primary study endpoint was to evaluate the outcome of patients with induced AAF in comparison to patients with ongoing AAF when starting the procedure. Furthermore, the investigators analyzed the type of recurrence during follow-up as well as the occurrence and results of repeat ablations at the institution. The investigators also evaluated if the recurrent AAF form was the same or de-novo compared to the AAF during previous procedure. conditions: Tachyarrhythmia conditions: Atypical Atrial Flutter conditions: Induction of Arryhthmia conditions: Clinical Outcome studyType: OBSERVATIONAL observationalModel: CASE_CONTROL timePerspective: RETROSPECTIVE count: 76 type: ACTUAL name: Induction of atypical atrial flutter measure: Outcome of patients with induced AAF in comparison to patients with ongoing AAF when starting the procedure. measure: Type of recurrence during follow-up measure: Occurrence and results of repeat ablations at our institution sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: University Hospital Essen city: Essen state: Nordrhein-Westfalen zip: 45147 country: Germany lat: 51.45657 lon: 7.01228 hasResults: False